miR‑155 promotes an inflammatory response in HaCaT cells via the IRF2BP2/KLF2/NF‑&kappa;B pathway in psoriasis

Chen,Lu; Liu,Chang; Xiang,Xuesong; Qiu,Wenhong; Guo,Kaiwen

doi:10.3892/ijmm.2024.5415

miR‑155 promotes an inflammatory response in HaCaT cells via the IRF2BP2/KLF2/NF‑κB pathway in psoriasis

Authors:
- Lu Chen
- Chang Liu
- Xuesong Xiang
- Wenhong Qiu
- Kaiwen Guo
View Affiliations

Affiliations: Department of Immunology, School of Medicine, Jianghan University, Wuhan, Hubei 430056, P.R. China, Department of Pathogenic Biology, Medical College, Wuhan University of Science and Technology, Wuhan, Hubei 430065, P.R. China
Published online on: August 21, 2024 https://doi.org/10.3892/ijmm.2024.5415
Article Number: 91
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Psoriasis is a chronic inflammatory skin condition with numerous causes, including genetic, immunological and infectious factors. The course of psoriasis is long and recurrence is common; pathogenesis is not completely understood. However, there is an association between advancement of psoriasis and aberrant microRNA (miR or miRNA)‑155 expression. Through bioinformatics, the present study aimed to analyze the differentially expressed genes and miRNAs in psoriasis and its biological mechanism and function psoriatic inflammation. First of all, differentially expressed genes (DEGs) and miRNAs (DEMs) in patients with psoriasis were identified using GEO2R interactive web application. A psoriasis inflammatory model was established using lipopolysaccharide (LPS)‑treated HaCaT keratinocytes, which were transfected with miR‑155 mimic or inhibitor. Cell Counting Kit‑8 was used for the assessment of cell viability and proliferation, and changes in the cell cycle were examined using flow cytometry. ELISA and reverse transcription‑quantitative PCR (RT‑qPCR) were used to detect the expression levels of the inflammatory factors IL‑1β and IL‑6. The dual‑luciferase reporter assay was used to verify the targeting association between miR‑155‑5p and IFN regulatory factor 2 binding protein 2 (IRF2BP2). To verify the targeting association of miR‑155 and the IRF2BP2/kruppel‑like factor 2 (KLF2)/NF‑κB signaling pathway, expression levels of IRF2BP2, KLF2 and p65 were identified by RT‑qPCR and western blotting. IRF2BP2 levels were also confirmed by immunofluorescence, in conjunction with bioinformatics database analysis. Overexpression of miR‑155 inhibited proliferation of HaCaT cells and increased the number of cells in S phase and decreasing number of cells in G1 and G2 phase. In the LPS‑induced inflammatory state, miR‑155 overexpression heightened the inflammatory response of HaCaT cells while inhibition of miR‑155 lessened it. Suppression of inflammatory cytokine expression by miR‑155‑5p inhibitor was reversed by knockdown of IRF2BP2. miR‑155 was shown to interact with IRF2BP2 to negatively regulate its expression, leading to decreased KLF2 expression and increased p65 expression and secretion of inflammatory factors, intensifying the inflammatory response of HaCaT cells. Therefore, miR‑155 may contribute to development of psoriasis by inducing tissue and cell damage by increasing the inflammatory response of HaCaT cells via the IRF2BP2/KLF2/NF‑κB pathway. In conclusion, the results of the present study offer novel perspectives on the role of miR‑155 in the onset and progression of psoriasis.

View Figures

View References

1	Boehncke WH and Schön MP: Psoriasis. Lancet. 386:983–994. 2015. View Article : Google Scholar : PubMed/NCBI
2	Hwang ST, Nijsten T and Elder JT: Recent highlights in psoriasis research. J Invest Dermatol. 137:550–556. 2017. View Article : Google Scholar : PubMed/NCBI
3	Chiricozzi A, Romanelli P, Volpe E, Borsellino G and Romanelli M: Scanning the immunopathogenesis of psoriasis. Int J Mol Sci. 19:1792018. View Article : Google Scholar : PubMed/NCBI
4	Ciccia F, Triolo G and Rizzo A: Psoriatic arthritis. N Engl J Med. 376:2094–2095. 2017. View Article : Google Scholar : PubMed/NCBI
5	Griffiths CEM, Armstrong AW, Gudjonsson JE and Barker JNWN: Psoriasis. Lancet. 397:1301–1315. 2021. View Article : Google Scholar : PubMed/NCBI
6	Dopytalska K, Czaplicka A, Szymańska E and Walecka I: The essential role of microRNAs in inflammatory and autoimmune skin diseases-a review. Int J Mol Sci. 24:91302023. View Article : Google Scholar : PubMed/NCBI
7	Dopytalska K, Ciechanowicz P, Wiszniewski K, Szymańska E and Walecka I: The role of epigenetic factors in psoriasis. Int J Mol Sci. 22:92942021. View Article : Google Scholar : PubMed/NCBI
8	Yang SC, Alalaiwe A, Lin ZC, Lin YC, Aljuffali IA and Fang JY: Anti-inflammatory microRNAs for treating inflammatory skin diseases. Biomolecules. 12:10722022. View Article : Google Scholar : PubMed/NCBI
9	Beer L, Kalinina P, Köcher M, Laggner M, Jeitler M, Abbas Zadeh S, Copic D, Tschachler E and Mildner M: miR-155 contributes to normal keratinocyte differentiation and is upregulated in the epidermis of psoriatic skin lesions. Int J Mol Sci. 21:92882020. View Article : Google Scholar : PubMed/NCBI
10	García-Rodríguez S, Arias-Santiago S, Blasco-Morente G, Orgaz-Molina J, Rosal-Vela A, Navarro P, Magro-Checa C, Martínez-López A, Ruiz JC, Raya E, et al: Increased expression of microRNA-155 in peripheral blood mononuclear cells from psoriasis patients is related to disease activity. J Eur Acad Dermatol Venereol. 31:312–322. 2017. View Article : Google Scholar
11	Xu L and Leng H, Shi X, Ji J, Fu J and Leng H: MiR-155 promotes cell proliferation and inhibits apoptosis by PTEN signaling pathway in the psoriasis. Biomed Pharmacother. 90:524–530. 2017. View Article : Google Scholar : PubMed/NCBI
12	Pastor TP, Peixoto BC and Viola JPB: The transcriptional co-factor IRF2BP2: A new player in tumor development and microenvironment. Front Cell Dev Biol. 9:6553072021. View Article : Google Scholar : PubMed/NCBI
13	Fagerberg L, Hallström BM, Oksvold P, Kampf C, Djureinovic D, Odeberg J, Habuka M, Tahmasebpoor S, Danielsson A, Edlund K, et al: Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. Mol Cell Proteomics. 13:397–406. 2014. View Article : Google Scholar :
14	Ma YL, Xia JL and Gao X: Suppressing Irf2bp2 expressions accelerates metabolic syndrome-associated brain injury and hepatic dyslipidemia. Biochem Biophys Res Commun. 503:1651–1658. 2018. View Article : Google Scholar : PubMed/NCBI
15	Ramalho-Oliveira R, Oliveira-Vieira B and Viola JPB: IRF2BP2: A new player in the regulation of cell homeostasis. J Leukoc Biol. 106:717–723. 2019. View Article : Google Scholar : PubMed/NCBI
16	Chen HH, Keyhanian K, Zhou X, Vilmundarson RO, Almontashiri NA, Cruz SA, Pandey NR, Lerma Yap N, Ho T, Stewart CA, et al: IRF2BP2 reduces macrophage inflammation and susceptibility to atherosclerosis. Circ Res. 117:671–683. 2015. View Article : Google Scholar : PubMed/NCBI
17	Cruz SA, Hari A, Qin Z, Couture P, Huang H, Lagace DC, Stewart AFR and Chen HH: Loss of IRF2BP2 in microglia increases inflammation and functional deficits after focal ischemic brain injury. Front Cell Neurosci. 11:2012017. View Article : Google Scholar : PubMed/NCBI
18	Feng X, Lu T, Li J, Yang R, Hu L, Ye Y, Mao F, He L, Xu J, Wang Z, et al: The tumor suppressor interferon regulatory factor 2 binding protein 2 regulates Hippo pathway in liver cancer by a feedback loop in mice. Hepatology. 71:1988–2004. 2020. View Article : Google Scholar
19	Hari A, Cruz SA, Qin Z, Couture P, Vilmundarson RO, Huang H, Stewart AFR and Chen HH: IRF2BP2-deficient microglia block the anxiolytic effect of enhanced postnatal care. Sci Rep. 7:98362017. View Article : Google Scholar : PubMed/NCBI
20	Li T, Luo Q, He L, Li D, Li Q, Wang C, Xie J and Yi C: Interferon regulatory factor-2 binding protein 2 ameliorates sepsis-induced cardiomyopathy via AMPK-mediated anti-inflammation and anti-apoptosis. Inflammation. 43:1464–1475. 2020. View Article : Google Scholar : PubMed/NCBI
21	Huang da W, Sherman BT and Lempicki RA: Bioinformatics enrichment tools: Paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 37:1–13. 2009. View Article : Google Scholar
22	Piruzian E, Bruskin S, Ishkin A, Abdeev R, Moshkovskii S, Melnik S, Nikolsky Y and Nikolskaya T: Integrated network analysis of transcriptomic and proteomic data in psoriasis. BMC Syst Biol. 4:412010. View Article : Google Scholar : PubMed/NCBI
23	Gauthier J, Vincent AT, Charette SJ and Derome N: A brief history of bioinformatics. Brief Bioinform. 20:1981–1996. 2019. View Article : Google Scholar
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
25	Ni X and Lai Y: Keratinocyte: A trigger or an executor of psoriasis? J Leukoc Biol. 108:485–491. 2020. View Article : Google Scholar : PubMed/NCBI
26	Xiuli Y and Honglin W: miRNAs flowing up and down: The concerto of psoriasis. Front Med (Lausanne). 8:6467962021. View Article : Google Scholar : PubMed/NCBI
27	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
28	Guo H, Ingolia NT, Weissman JS and Bartel DP: Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature. 466:835–840. 2010. View Article : Google Scholar : PubMed/NCBI
29	Jinnin M: Various applications of microRNAs in skin diseases. J Dermatol Sci. 74:3–8. 2014. View Article : Google Scholar : PubMed/NCBI
30	Wu R, Zeng J, Yuan J, Deng X, Huang Y, Chen L, Zhang P, Feng H, Liu Z, Wang Z, et al: MicroRNA-210 overexpression promotes psoriasis-like inflammation by inducing Th1 and Th17 cell differentiation. J Clin Invest. 128:2551–2568. 2018. View Article : Google Scholar : PubMed/NCBI
31	Raaby L, Langkilde A, Kjellerup RB, Vinter H, Khatib SH, Hjuler KF, Johansen C and Iversen L: Changes in mRNA expression precede changes in microRNA expression in lesional psoriatic skin during treatment with adalimumab. Br J Dermatol. 173:436–447. 2015. View Article : Google Scholar : PubMed/NCBI
32	Sonkoly E, Wei T, Janson PC, Sääf A, Lundeberg L, Tengvall-Linder M, Norstedt G, Alenius H, Homey B, Scheynius A, et al: MicroRNAs: Novel regulators involved in the pathogenesis of psoriasis? PLoS One. 2:e6102007. View Article : Google Scholar : PubMed/NCBI
33	Liu Q, Wu DH, Han L, Deng JW, Zhou L, He R, Lu CJ and Mi QS: Roles of microRNAs in psoriasis: Immunological functions and potential biomarkers. Exp Dermatol. 26:359–367. 2017. View Article : Google Scholar
34	Luo Q, Zeng J, Li W, Lin L, Zhou X, Tian X, Liu W, Zhang L and Zhang X: Silencing of miR-155 suppresses inflammatory responses in psoriasis through inflammasome NLRP3 regulation. Int J Mol Med. 42:1086–1095. 2018.PubMed/NCBI
35	Liu Y, Zhao X, Li J, Zhou L, Chang W, Li J, Hou R, Li J, Yin G, Li X and Zhang K: MiR-155 inhibits TP53INP1 expression leading to enhanced glycolysis of psoriatic mesenchymal stem cells. J Dermatol Sci. 105:142–151. 2022. View Article : Google Scholar : PubMed/NCBI
36	Wang H, Zhang Y, Luomei J, Huang P, Zhou R and Peng Y: The miR-155/GATA3/IL37 axis modulates the production of proinflammatory cytokines upon TNF-α stimulation to affect psoriasis development. Exp Dermatol. 29:647–658. 2020. View Article : Google Scholar : PubMed/NCBI
37	Koeppel M, van Heeringen SJ, Smeenk L, Navis AC, Janssen-Megens EM and Lohrum M: The novel p53 target gene IRF2BP2 participates in cell survival during the p53 stress response. Nucleic Acids Res. 37:322–335. 2009. View Article : Google Scholar
38	Liang Y, Zhou Y and Shen P: NF-kappaB and its regulation on the immune system. Cell Mol Immunol. 1:343–350. 2004.
39	Wu J, Ding J, Yang J, Guo X and Zheng Y: MicroRNA roles in the nuclear factor kappa B signaling pathway in cancer. Front Immunol. 9:5462018. View Article : Google Scholar : PubMed/NCBI
40	Alexandrov P, Zhai Y, Li W and Lukiw W: Lipopolysaccharide-stimulated, NF-kB-, miRNA-146a- and miRNA-155-mediated molecular-genetic communication between the human gastrointestinal tract microbiome and the brain. Folia Neuropathol. 57:211–219. 2019. View Article : Google Scholar : PubMed/NCBI
41	McConnell BB and Yang VW: Mammalian Krüppel-like factors in health and diseases. Physiol Rev. 90:1337–1381. 2010. View Article : Google Scholar : PubMed/NCBI
42	Jha P and Das H: KLF2 in regulation of NF-κB-mediated immune cell function and inflammation. Int J Mol Sci. 18:23832017. View Article : Google Scholar
43	Das M, Lu J, Joseph M, Aggarwal R, Kanji S, McMichael BK, Lee BS, Agarwal S, Ray-Chaudhury A, Iwenofu OH, et al: Kruppel-like factor 2 (KLF2) regulates monocyte differentiation and functions in mBSA and IL-1β-induced arthritis. Curr Mol Med. 12:113–125. 2012. View Article : Google Scholar : PubMed/NCBI
44	Mahabeleshwar GH, Qureshi MA, Takami Y, Sharma N, Lingrel JB and Jain MK: A myeloid hypoxia-inducible factor 1α-Krüppel-like factor 2 pathway regulates gram-positive endotoxin-mediated sepsis. J Biol Chem. 287:1448–1457. 2012. View Article : Google Scholar
45	Novodvorsky P and Chico TJA: The role of the transcription factor KLF2 in vascular development and disease. Prog Mol Biol Transl Sci. 124:155–188. 2014. View Article : Google Scholar : PubMed/NCBI
46	Das H, Kumar A, Lin Z, Patino WD, Hwang PM, Feinberg MW, Majumder PK and Jain MK: Kruppel-like factor 2 (KLF2) regulates proinflammatory activation of monocytes. Proc Natl Acad Sci USA. 103:6653–6658. 2006. View Article : Google Scholar : PubMed/NCBI
47	Mahabeleshwar GH, Kawanami D, Sharma N, Takami Y, Zhou G, Shi H, Nayak L, Jeyaraj D, Grealy R, White M, et al: The myeloid transcription factor KLF2 regulates the host response to polymicrobial infection and endotoxic shock. Immunity. 34:715–728. 2011. View Article : Google Scholar : PubMed/NCBI
48	Nayak L, Goduni L, Takami Y, Sharma N, Kapil P, Jain MK and Mahabeleshwar GH: Kruppel-like factor 2 is a transcriptional regulator of chronic and acute inflammation. Am J Pathol. 182:1696–1704. 2013. View Article : Google Scholar : PubMed/NCBI
49	SenBanerjee S, Lin Z, Atkins GB, Greif DM, Rao RM, Kumar A, Feinberg MW, Chen Z, Simon DI, Luscinskas FW, et al: KLF2 Is a novel transcriptional regulator of endothelial proinflammatory activation. J Exp Med. 199:1305–1315. 2004. View Article : Google Scholar : PubMed/NCBI
50	Masalha M, Sidi Y and Avni D: The contribution of feedback loops between miRNAs, cytokines and growth factors to the pathogenesis of psoriasis. Exp Dermatol. 27:603–610. 2018. View Article : Google Scholar : PubMed/NCBI